Phesgo and Tecentriq Performance and Approvals

Q1 2023: Strong momentum for key growth drivers Vabysmo leading growth contributor after only 5 quarters Vabysmo Ocrevus Hemlibra Evrysdi Tecentriq Perjeta Phesgo Tamiflu Polivy TNKase/Activase Ronapreve Gazyva Alecensa Kadcyla Xolair Xofluza Lucentis Actemra/RoActemra MabThera Herceptin Avastin Esbriet 14% 24% 62% 15% 11% 72% >500% 96% 23% 9% >500% 24% 9% 5% 5% >500% -35% -12% -17% -17% US Europe ■Japan -24% International -69% T -300 -200 -100 0 100 200 300 400 500 Absolute values and growth rates at Constant Exchange Rates (CER) Roche 18

View entire presentation